Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Renzapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 7/20 | 0.98 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.98 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.98 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.98 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | HTR5A | P47898 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Renzapride SCHEMBL5765864 | 1.00 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371909 | 1.00 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5767174 | 0.99 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371617 | 0.99 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL17037 | 0.99 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL678616 | 0.99 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL4534994 | 0.99 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1650356 | 0.97 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8292934 | 0.88 | HTR3A (0.80) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL667580 | 0.88 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | claimed |
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | PFIZER INC | 2006-06-01 | — | — | US | claimed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | claimed |
| EP-0239321-B1 | CHEMICAL COMPOUND | BEECHAM GROUP PLC (GB) | 1993-06-16 | — | — | EP | claimed |
| EP-0239321-A2 | Chemical compound | BEECHAM GROUP PLC (GB) | 1987-09-30 | — | — | EP | claimed |
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1664048-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | Alizyme Therapeutics Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | PFIZER INC | 2006-06-01 | — | — | US | disclosed |
| US-20050049416-A1 | Synthesis | ENDOLOGIC LLC | 2005-03-03 | — | — | US | disclosed |
| US-20050049416-A1 | Synthesis | ENDOLOGIC LLC | 2005-03-03 | — | — | US | disclosed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | disclosed |
| EP-0560348-B1 | Thieno 3,2-b pyridine derivatives for the treatment of gastrointestinal disorders | MITSUBISHI CHEM CORP (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-5352685-A | Gastrointestinal disorders | MITSUBISHI KASEI CORPORATION (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0560348-A1 | Thieno 3,2-b pyridine derivatives for the treatment of gastrointestinal disorders | Mitsubishi Chemical Corporation (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-4800225-A | Pharmacologically active hydrated azabicyclo compound | BEECHAM GROUP, P.L.C. (GB) | 1989-01-24 | — | — | US | disclosed |
| EP-0239321-A2 | Chemical compound | BEECHAM GROUP PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049416-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | HTR3A 602/4885HTR3E 953/4885HTR3B 795/4885 |
| US-20070135641-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | HTR3A 602/4885HTR3E 953/4885HTR3B 795/4885 |
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | CYP7B1, P2RX7, CYP3A7 | HTR3A 791/4885HTR3E 1732/4885HTR3B 537/4885 |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | CYP1B1, TPMT, CYP7B1 | HTR3A 2651/4885HTR3E 3531/4885HTR3B 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.